Cargando…
Extracorporeal Life Support in Adult Patients with Hematologic Malignancies and Acute Circulatory and/or Respiratory Failure
BACKGROUND: The primary goal of this study was to characterize the clinical outcomes of adult patients with hematologic malignancies (HM) who were treated with extracorporeal membrane oxygenation (ECMO) support when conventional treatments failed. METHODS: In this retrospective, observational study...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society for Thoracic and Cardiovascular Surgery
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383857/ https://www.ncbi.nlm.nih.gov/pubmed/30834214 http://dx.doi.org/10.5090/kjtcs.2019.52.1.25 |
_version_ | 1783396904492597248 |
---|---|
author | Cho, Sungbin Cho, Won Chul Lim, Ju Yong Kang, Pil Je |
author_facet | Cho, Sungbin Cho, Won Chul Lim, Ju Yong Kang, Pil Je |
author_sort | Cho, Sungbin |
collection | PubMed |
description | BACKGROUND: The primary goal of this study was to characterize the clinical outcomes of adult patients with hematologic malignancies (HM) who were treated with extracorporeal membrane oxygenation (ECMO) support when conventional treatments failed. METHODS: In this retrospective, observational study at a tertiary medical center, we reviewed the clinical course of 23 consecutive patients with HM requiring ECMO who were admitted to the intensive care unit at Asan Medical Center from March 2010 to April 2015. RESULTS: A total of 23 patients (8 female; median age, 44 years; range, 29–51 years) with HM and severe acute circulatory and/or respiratory failure received ECMO therapy during the study period. Fourteen patients received veno-arterial ECMO, while 9 patients received veno-venous ECMO. The median ECMO duration was 104.7 hours (range, 37.1–221 hours). Nine patients were successfully weaned from ECMO. The in-hospital mortality rate was 91.1% (21 of 23). There were complications in 3 patients (cannulation site bleeding, limb ischemia, and gastrointestinal bleeding). CONCLUSION: ECMO is a useful treatment for patients with circulatory and/or pulmonary failure. However, in patients with HM, the outcomes of ECMO treatment results were very poor, so it is advisable to carefully decide whether to apply ECMO to these patients. |
format | Online Article Text |
id | pubmed-6383857 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | The Korean Society for Thoracic and Cardiovascular Surgery |
record_format | MEDLINE/PubMed |
spelling | pubmed-63838572019-03-04 Extracorporeal Life Support in Adult Patients with Hematologic Malignancies and Acute Circulatory and/or Respiratory Failure Cho, Sungbin Cho, Won Chul Lim, Ju Yong Kang, Pil Je Korean J Thorac Cardiovasc Surg Clinical Research BACKGROUND: The primary goal of this study was to characterize the clinical outcomes of adult patients with hematologic malignancies (HM) who were treated with extracorporeal membrane oxygenation (ECMO) support when conventional treatments failed. METHODS: In this retrospective, observational study at a tertiary medical center, we reviewed the clinical course of 23 consecutive patients with HM requiring ECMO who were admitted to the intensive care unit at Asan Medical Center from March 2010 to April 2015. RESULTS: A total of 23 patients (8 female; median age, 44 years; range, 29–51 years) with HM and severe acute circulatory and/or respiratory failure received ECMO therapy during the study period. Fourteen patients received veno-arterial ECMO, while 9 patients received veno-venous ECMO. The median ECMO duration was 104.7 hours (range, 37.1–221 hours). Nine patients were successfully weaned from ECMO. The in-hospital mortality rate was 91.1% (21 of 23). There were complications in 3 patients (cannulation site bleeding, limb ischemia, and gastrointestinal bleeding). CONCLUSION: ECMO is a useful treatment for patients with circulatory and/or pulmonary failure. However, in patients with HM, the outcomes of ECMO treatment results were very poor, so it is advisable to carefully decide whether to apply ECMO to these patients. The Korean Society for Thoracic and Cardiovascular Surgery 2019-02 2019-02-05 /pmc/articles/PMC6383857/ /pubmed/30834214 http://dx.doi.org/10.5090/kjtcs.2019.52.1.25 Text en Copyright © 2019 by The Korean Society for Thoracic and Cardiovascular Surgery. All rights Reserved. This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Research Cho, Sungbin Cho, Won Chul Lim, Ju Yong Kang, Pil Je Extracorporeal Life Support in Adult Patients with Hematologic Malignancies and Acute Circulatory and/or Respiratory Failure |
title | Extracorporeal Life Support in Adult Patients with Hematologic Malignancies and Acute Circulatory and/or Respiratory Failure |
title_full | Extracorporeal Life Support in Adult Patients with Hematologic Malignancies and Acute Circulatory and/or Respiratory Failure |
title_fullStr | Extracorporeal Life Support in Adult Patients with Hematologic Malignancies and Acute Circulatory and/or Respiratory Failure |
title_full_unstemmed | Extracorporeal Life Support in Adult Patients with Hematologic Malignancies and Acute Circulatory and/or Respiratory Failure |
title_short | Extracorporeal Life Support in Adult Patients with Hematologic Malignancies and Acute Circulatory and/or Respiratory Failure |
title_sort | extracorporeal life support in adult patients with hematologic malignancies and acute circulatory and/or respiratory failure |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383857/ https://www.ncbi.nlm.nih.gov/pubmed/30834214 http://dx.doi.org/10.5090/kjtcs.2019.52.1.25 |
work_keys_str_mv | AT chosungbin extracorporeallifesupportinadultpatientswithhematologicmalignanciesandacutecirculatoryandorrespiratoryfailure AT chowonchul extracorporeallifesupportinadultpatientswithhematologicmalignanciesandacutecirculatoryandorrespiratoryfailure AT limjuyong extracorporeallifesupportinadultpatientswithhematologicmalignanciesandacutecirculatoryandorrespiratoryfailure AT kangpilje extracorporeallifesupportinadultpatientswithhematologicmalignanciesandacutecirculatoryandorrespiratoryfailure |